FBIO
Fortress Biotech, Inc.
There isn't enough reported data to score FBIO yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
FBIO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Unavailable | |
| Unavailable |
FBIO's revenue is currently healthy, and its profitability is stable. There isn't enough data to rate its cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
FBIO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 0.7x | $2.01 | +0.8% |
| Current | 0.7x | $1.99 | — |
| Fair | 0.9x | $2.32 | +17% |
| Expensive | 1x | $2.77 | +39% |
Historical ranges are pointers, not guarantees.
FBIO's PE is 0.7x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
FBIO Forward outlook
There aren't enough analyst estimates for FBIO to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
FBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $2.70 | +$3.66 |
| Q1 2026 | $3.23 | +$5.37 |
| Q4 2025 | -$0.07 | +$2.62 |
| Q3 2023 | -$12.19 | +$3.56 |
| Q2 2023 | -$15.00 | +$0.90 |
| Q1 2023 | -$15.00 | -$2.10 |
| Q4 2022 | -$14.55 | -$2.70 |
| Q3 2022 | -$15.75 | -$8.55 |
FBIO has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
FBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $18.7M | +14% |
| Q1 2026 | $16M | +22% |
| Q4 2025 | $16.1M | +6.3% |
| Q3 2025 | $17.6M | +21% |
| Q2 2025 | $16.4M | +10% |
| Q1 2025 | $13.1M | +0.8% |
| Q4 2024 | $15.1M | -24% |
| Q3 2024 | $14.6M | -58% |
FBIO's revenue is recovering but still below its 2023 peak: $19M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -53% | +169 points |
| Q1 2026 | -48% | +122 points |
| Q4 2025 | -30% | +128 points |
| Q3 2025 | -39% | +112 points |
| Q2 2025 | -222% | -36 points |
| Q1 2025 | -170% | +111 points |
| Q4 2024 | -158% | -59 points |
| Q3 2024 | -151% | -111 points |
FBIO's operating margin was −53% last quarter, up 169 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over FBIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over FBIO on profitability, with a higher operating margin.
FBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | $203.9M | +$223.4M |
| Q4 2025 | -$12.5M | +$363K |
| Q3 2025 | -$6.1M | +$13.9M |
| Q1 2025 | -$19.6M | +$5.8M |
| Q4 2024 | -$12.9M | +$22.1M |
| Q3 2024 | -$20.1M | -$3.3M |
| Q1 2024 | -$25.4M | +$17.8M |
| Q4 2023 | -$35M | +$13M |
FBIO has the stronger cash trend. Its trailing FCF is up 243% versus its history, compared with HIMS at down 84%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
FBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -17% | -6.6M shares |
| 1 year | +6.6% | +2M shares |
| 3 years | +437% | +25.9M shares |
| 5 years | +527% | +26.7M shares |
FBIO has 32M diluted shares, up 6.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over FBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
FBIO Net Leverage
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
FBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.7 | Neutral |
| Stochastic | 8.6 | Oversold |
FBIO's weekly RSI is 38 (neutral) and its Stochastic is 9 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
FBIO PE vs Healthcare Sector
| Metric | FBIO | Sector median | Relative |
|---|---|---|---|
| PE | 0.7x | 26x | 97% below |
| PE % | 15 | 29 | 14 pts below |
FBIO is trading at 0.7x earnings, a 97% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
FBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.00 | 0.5% below |
| 20 week MA | $2.56 | 22% below |
| 50 week MA | $2.84 | 30% below |
| 100 week MA | $2.49 | 20% below |
| 200 week MA | $3.62 | 45% below |
FBIO is in a downtrend: it's below all five of its weekly moving averages, and 45% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
FBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37.1 | $51.5 | +39% |
| 2021 | $51.5 | $39.3 | -24% |
| 2022 | $39.3 | $8.25 | -79% |
| 2023 | $8.25 | $3.01 | -64% |
| 2024 | $3.01 | $2.36 | -22% |
| 2025 | $2.36 | $3.74 | +58% |
| 2026 YTD | $3.74 | $1.99 | -47% |
FBIO has finished lower in four of the last six years. It's down 47% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over FBIO on returns for 2026, with the stronger performance.